| pubmed-article:9592190 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9592190 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9592190 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9592190 | lifeskim:mentions | umls-concept:C1135161 | lld:lifeskim |
| pubmed-article:9592190 | lifeskim:mentions | umls-concept:C0280849 | lld:lifeskim |
| pubmed-article:9592190 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:9592190 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9592190 | pubmed:dateCreated | 1998-7-22 | lld:pubmed |
| pubmed-article:9592190 | pubmed:abstractText | 3F8 is an IgG3 murine monoclonal antibody directed against the ganglioside GD2. In a phase II study, 3F8 was administered i.v. to 16 patients (pts) who had stage 4 neuroblastoma. Response was seen in bony lesions (2 of 7 pts) and marrow (3 of 8 pts). Acute toxicities of pain, fever, urticaria, hypertension, hypotension and anaphylactoid reactions were self-limited and manageable. Three pts are long-term survivors between 79-130+ months after 3F8 treatment without additional systemic therapy and no delayed neurological complications. The potential benefits of 3F8 when added to chemoradio-therapy warrant further investigation. | lld:pubmed |
| pubmed-article:9592190 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592190 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9592190 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592190 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9592190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9592190 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9592190 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9592190 | pubmed:issn | 1019-6439 | lld:pubmed |
| pubmed-article:9592190 | pubmed:author | pubmed-author:CheungN KNK | lld:pubmed |
| pubmed-article:9592190 | pubmed:author | pubmed-author:YehS DSD | lld:pubmed |
| pubmed-article:9592190 | pubmed:author | pubmed-author:LarsonS MSM | lld:pubmed |
| pubmed-article:9592190 | pubmed:author | pubmed-author:KushnerB HBH | lld:pubmed |
| pubmed-article:9592190 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9592190 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:9592190 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9592190 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9592190 | pubmed:pagination | 1299-306 | lld:pubmed |
| pubmed-article:9592190 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:meshHeading | pubmed-meshheading:9592190-... | lld:pubmed |
| pubmed-article:9592190 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9592190 | pubmed:articleTitle | 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. | lld:pubmed |
| pubmed-article:9592190 | pubmed:affiliation | Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. | lld:pubmed |
| pubmed-article:9592190 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9592190 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9592190 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9592190 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9592190 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9592190 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9592190 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9592190 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9592190 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9592190 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9592190 | lld:pubmed |
